Ignite Creation Date:
2025-12-24 @ 9:42 PM
Ignite Modification Date:
2025-12-30 @ 6:59 PM
Study NCT ID:
NCT00622232
Status:
UNKNOWN
Last Update Posted:
2011-06-08
First Post:
2008-02-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015658', 'term': 'HIV Infections'}], 'ancestors': [{'id': 'D000086982', 'term': 'Blood-Borne Infections'}, {'id': 'D003141', 'term': 'Communicable Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D015229', 'term': 'Sexually Transmitted Diseases, Viral'}, {'id': 'D012749', 'term': 'Sexually Transmitted Diseases'}, {'id': 'D016180', 'term': 'Lentivirus Infections'}, {'id': 'D012192', 'term': 'Retroviridae Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D007153', 'term': 'Immunologic Deficiency Syndromes'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 40}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2007-12'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2011-06', 'completionDateStruct': {'date': '2023-06', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2011-06-07', 'studyFirstSubmitDate': '2008-02-11', 'studyFirstSubmitQcDate': '2008-02-21', 'lastUpdatePostDateStruct': {'date': '2011-06-08', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2008-02-22', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2009-01', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'To evaluate the safety and tolerability of an additional infusion of VRX496 CD4+ T cells in subjects who previously received VRX496 CD4 T cells under protocol VRX496-USA-05-002.', 'timeFrame': '9 months'}, {'measure': 'To evaluate the change in log10 HIV-1 RNA level', 'timeFrame': '9 months'}, {'measure': 'To evaluate the change between main study baseline CD4 counts and Month 9 post reinfusion', 'timeFrame': '9 months'}], 'secondaryOutcomes': [{'measure': 'Changes in immune function as determined by ICS and TCR vβ Repertoire profile.', 'timeFrame': '9 months'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['HIV-1', 'treatment experienced, complementary therapies'], 'conditions': ['HIV Infections']}, 'descriptionModule': {'briefSummary': 'The objective of this study is to determine the long term safety and tolerability of an additional infusion of 10 billion VRX496 gene-modified CD4 T cells with a focus on evaluating additional therapeutic benefits with respect to viral load and CD4 counts.', 'detailedDescription': "The study has concluded it's 9-month active phase. Subjects are currently in a 15-year Long Term Follow-up Phase of the study.\n\nIn keeping with the recently released Guidance on Monitoring For Delayed Adverse Events, that states that for the first 5 years all subjects should undergo monitoring of vector sequences every 6 months, subjects will visit the clinic at a maximum of 6 months intervals for a blood test evaluating persistence of vector sequences.\n\nTherefore for the first 5 years, subjects will have 6 months visits for safety assessment. For years 6 to 15, subjects will be contacted by phone or mail. At these contacts, subjects will be asked about their health status."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Ability and willingness to give written informed consent in accordance with institutional and federal guidelines and to comply with the investigational nature of the study and the related requirements.\n* Subjects who have successfully completed participation in the VRX496-USA-05-002 trial.\n* Subjects who initiated or changed to a new ARV regimen more than 3 months prior to Entry Assessment are eligible.\n* Subjects that who (1) if on ARVs and are willing to continue on the current therapy unchanged, or (2) if not on ARV willing to remain off ARVs for the duration of the trial i.e. 9 months. However, if there is clinical need to start or change ARV therapy, then it is permitted to do so.\n\nExclusion Criteria:\n\n* CD4 counts decreased by ≥25% from baseline in main study.\n* Viral load increased by ≥ 1.0 log from baseline in main study or ≥ 200,000.\n* Female subjects who are of reproductive potential who have a positive serum B HCG at the Entry Assessment visit or are not willing to use a reliable method of barrier contraception.\n* Are breast-feeding.\n* Subjects who are actively using injection drugs or other substance abuse (such as extensive alcohol or narcotic use).\n* Any medical condition(s) which, in the opinion of the investigator, would interfere with the subject's ability to participate in or adhere to the requirements of this protocol\n* Active HIV-related or non HIV-related illness\n* Subjects who do not have additional cell product available"}, 'identificationModule': {'nctId': 'NCT00622232', 'acronym': 'Rollover', 'briefTitle': 'A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial', 'organization': {'class': 'INDUSTRY', 'fullName': 'VIRxSYS Corporation'}, 'officialTitle': 'A Rollover Study to Evaluate Safety and Therapeutic Effect of Re-infusing Subjects Who Completed Participation in the VRX496-USA-05-002 Trial With Autologous T Cells Transduced With VRX496', 'orgStudyIdInfo': {'id': 'VRX496-USA-05-002-Rollover'}}, 'armsInterventionsModule': {'interventions': [{'name': 'VRX496-transduced autologous CD4 T cells', 'type': 'GENETIC', 'description': 'The cell dose will consist of approximately 10 billion VRX496-transduced autologous CD4 T cells provided as a single bolus infusion.'}]}, 'contactsLocationsModule': {'locations': [{'zip': '06851', 'city': 'Norwalk', 'state': 'Connecticut', 'country': 'United States', 'facility': 'CIRCLE Medical, LLC', 'geoPoint': {'lat': 41.1176, 'lon': -73.4079}}, {'zip': '10461', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Jacobi Medical Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}], 'overallOfficials': [{'name': 'Tessio E Rebello, PhD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'VIRxSYS Corporation'}, {'name': 'David Stein, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Jacobi Medical Center'}, {'name': 'Gary Blick, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'CIRCLE Medical, LLC'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'VIRxSYS Corporation', 'class': 'INDUSTRY'}, 'responsibleParty': {'oldNameTitle': 'Tessio Rebello, PhD/Vice President of Clinical Affairs', 'oldOrganization': 'VIRxSYS Corporation'}}}}